JW Asset Management Llc sells out 97,300 shares as the company’s stock turn
down up to 4.62% while stock markets rallied. The institutional investor held
760,379 shares of the health care company at the end of 2016, valued at
$30.80M, down from 857,679 at the end of the previously reported quarter. JW
Asset Management Llc who had been investing in Eagle Pharmaceuticals Inc for a
number of months seems to be less bullish one the $1.09B market cap company.
Eagle Pharmaceuticals Inc (NASDAQ:EGRX) has risen 3.50% since March 1, 2016,
and is up trending. It has underperformed by 5.74% the S&P500.
Eagle’s CEO and President Scott Tarriff exclaimed a statement “as many
pharmaceutical companies all over the world invest in biosimilars, eagle, and Arsia
combined know-how and execution capabilities will permit us to improve upon
those formulations to create bio-betters, which according to us is the key to
product pricing power, differentiation, and large market share.” Eagle agreed to
pay 30 million dollars at closing for Arsia and will be paid in cash.
The technology developed by Arsia promises tremendous ways for solving a
variety of fundamental pharmaceuticals challenges and difficulties. The company
itself said that but joining forces with eagle they are excited to expand the
application of this technology to address many challenges with a variety of
therapeutic agents. Eagle also said that they are planning to found a biologics
innovation center in Cambridge, Massachusetts.
About Eagle Pharmaceuticals
Eagle is a pharmaceutical company with a full focus on commercializing and
developing injectable products that address the shortcomings as identified by
pharmacists, physicians, and stakeholders. Eagle’s key strategy is to use FDA’s
regulatory pathway. Their products have the potential to benefit both healthcare
and patients. This company is committed to conducting business according to
highest ethical standards.